Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period of March 2022. The registrant is a foreign private issuer based in Israel. The filing discloses a material corporate transaction: a registered direct offering of equity and warrants entered into on March 1, 2022, with an expected closing date of March 3, 2022.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10,000,000 from the sale of 20,000,000 ordinary shares and accompanying warrants.
- Offering Price: $0.50 per ordinary share and accompanying Investor Warrant.
- Warrant Terms: Investors received warrants to purchase up to 15,000,000 ordinary shares (0.75 warrant per share) at an exercise price of $0.65 per share, expiring March 3, 2027.
- Placement Agent Fees: 7.0% of gross proceeds plus a 1.0% management fee, $70,000 expense allowance, and warrants to purchase 1,000,000 shares (5% of the offering) at $0.625 per share.
- Use of Proceeds: Funding the clinical development of C-Scan (including a U.S. pivotal study) and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Amendments
In conjunction with the new offering, the Company amended terms for existing "July Warrants" issued to investors in July 2021:
- Exercise Price Reduction: The exercise price for 18,525,927 existing warrants was reduced to $0.65 per share.
- Term Extension: The exercise period for these existing warrants was extended to January 2, 2025.
Guidance, Outlook, and Restrictions
Management intends to utilize net proceeds to advance the clinical development of its C-Scan technology. The filing includes significant market restrictions:
- Lock-up Period: The Company agreed not to issue or announce the issuance of ordinary shares or equivalents for 90 days following the closing.
- Variable Rate Transaction Ban: The Company is prohibited from entering into variable rate transactions for 12 months following the closing.
Investor Verification Checklist
- Verify the actual closing date of the offering and confirmation of the $10,000,000 gross proceeds receipt.
- Review the impact of the warrant exercise price reduction ($0.65) on existing shareholder dilution.
- Monitor the progress of the C-Scan U.S. pivotal study as the primary use of funds.
- Check for any subsequent filings regarding the exercise of the new Investor Warrants or Placement Agent Warrants.